News & Events – Sumitovant

Select Company

December 23, 2020Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
November 24, 2020Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 12, 2020Sumitovant Biopharma and Urovant Sciences Announce Sumitovant’s Acquisition of Remaining Stake in Urovant
October 07, 2020Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
August 13, 2020Urovant Sciences Reports Fiscal First Quarter 2020 Results
June 18, 2020Urovant Sciences Reports Fiscal Year and Fourth Quarter 2019 Results
June 18, 2020Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
May 27, 2020Urovant Sciences Appoints James Hindman to Board of Directors
May 26, 2020Urovant Sciences to Present at the Jefferies Virtual Healthcare Conference
May 14, 2020Urovant Sciences Presents Positive Clinical Efficacy & Safety Data on Lead Drug Candidate Vibegron at Virtual American Urological Association Annual Meeting
1 2 3 … 5 Next »